Zhitong Finance App News, ST Renfu (600079.SH) issued an announcement. Hubei Biomedical Industry Technology Research Institute Co., Ltd. (hereinafter referred to as “Research Institute Co., Ltd.”), a wholly-owned subsidiary of the company, recently announced HW201877 capsule phase IIa clinical trial registration information on the drug clinical trial registration and information disclosure platform of the China Drug Administration.

HW201877 capsules obtained the “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration in March 2025 (the clinical trial applicant was Wuhan Renfu Innovative Drug Research and Development Center Co., Ltd., a wholly-owned subsidiary of the company, transferred to Research Institute Co., Ltd. in September 2026). The approved clinical indication is inflammatory bowel disease. Inflammatory bowel disease (IBD) is a chronic, nonspecific, recurrent, and inflammatory disease that mainly affects the gastrointestinal tract, mainly including ulcerative colitis (UC) and Crohn's disease (CD). According to statistics from the Insight database, there are currently no drugs with the same target or indication on the market in China. Up to now, the total R&D investment for the project is about 60 million yuan.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.